Current status of gadolinium toxicity in patients with kidney disease.
about
Nephrogenic systemic fibrosis: a survey of nephrologists' perceptions and practices.Role of magnetic resonance imaging in the detection and characterization of solid pancreatic nodules: An updateX-ray-computed tomography contrast agentsCurrent opinions in renovascular hypertensionACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents.Hyperpolarized water as an MR imaging contrast agent: feasibility of in vivo imaging in a rat modelNanoparticles based on star polymers as theranostic vectors: endosomal-triggered drug release combined with MRI sensitivity.Biocompatible nanoparticles of KGd(H₂O)₂[Fe(CN)₆]·H₂O with extremely high T₁-weighted relaxivity owing to two water molecules directly bound to the Gd(III) centerFunctional nanoparticles for magnetic resonance imaging.Evaluation and comparison of diffusion MR methods for measuring apparent transcytolemmal water exchange rate constant.Continuous flow Overhauser dynamic nuclear polarization of water in the fringe field of a clinical magnetic resonance imaging system for authentic image contrastContrast-induced acute kidney injury and renal support for acute kidney injury: a KDIGO summary (Part 2).Can Ultrasound With Contrast Enhancement Replace Nonenhanced Computed Tomography Scans in Patients With Contraindication to Computed Tomography Contrast Agents?Accidental and iatrogenic causes of acute kidney injury.Applications of molecular MRI and optical imaging in cancer.Current status and future perspectives of magnetic resonance high-field imaging: a summaryASCI 2010 contrast media guideline for cardiac imaging: a report of the Asian Society of Cardiovascular Imaging cardiac computed tomography and cardiac magnetic resonance imaging guideline working group.Type of MRI contrast, tissue gadolinium, and fibrosis.Pituitary involvement in Wegener's granulomatosis: unusual biochemical findings and severe malnutrition.Nanomedical Theranostics in Cardiovascular Disease.Scan-stratified case-control sampling for modeling blood-brain barrier integrity in multiple sclerosis.Pharmacokinetics and magnetic resonance imaging of biodegradable macromolecular blood-pool contrast agent PG-Gd in non-human primates: a pilot study.A fast and effective determination of the biodistribution and subcellular localization of fluorescent immunoliposomes in freshly excised animal organs.Continuous-flow DNP polarizer for MRI applications at 1.5 T.Gadolinium-based contrast agents for magnetic resonance cancer imaging.Predicting breakdown of the blood-brain barrier in multiple sclerosis without contrast agents.Safety Report of Ferumoxytol for Magnetic Resonance Imaging in Children and Young AdultsMR - eyes for cancer: looking within an impenetrable diseaseChanges in Urinary and Serum Levels of Novel Biomarkers after Administration of Gadolinium-based Contrast Agents.Introductory Chemistry: A Molar Relaxivity Experiment in the High School Classroom.Lack of nephrotoxicity of gadopentetate dimeglumine-enhanced non-vascular MRI and MRI without contrast agent in patients at high-risk for acute kidney injury.Peripheral artery disease. Part 1: clinical evaluation and noninvasive diagnosis.Measurement of kidney perfusion in critically ill patients.The prominent role of cardiac magnetic resonance imaging in coronary artery disease.Upconverting nanoparticles: assessing the toxicity.The issues and tentative solutions for contrast-enhanced magnetic resonance imaging at ultra-high field strength.Dendritic nanoglobules with polyhedral oligomeric silsesquioxane core and their biomedical applications.Identifying the Adamkiewicz artery using 3-T time-resolved magnetic resonance angiography: its role in addition to multidetector computed tomography angiography.Perspectives and challenges of photon-upconversion nanoparticles - Part II: bioanalytical applications.How to Provide Gadolinium-Free PET/MR Cancer Staging of Children and Young Adults in Less than 1 h: the Stanford Approach.
P2860
Q24602293-A2E47E38-3A90-46E3-A930-39526804C5DEQ26773662-8A5CF83E-2BB7-4C5A-8A5A-2DA7EC43BEBBQ28280706-E3240F81-CE06-4F5E-95CC-11468CDBB5B0Q28289306-9F5C9B05-8486-4501-800B-3979139DD8A2Q30475186-C5521AB7-DFBF-4245-8E69-916D8D3EE632Q30569663-4392E096-108F-41E8-B3DA-BC5556B91E00Q30834488-4C717246-8868-44AB-B157-7A759C5342C4Q30853878-B2288E84-EA77-460D-8AA7-22537B001BC8Q31067306-6E6B2C77-03B8-47F3-BEA8-35E55E79F48DQ31148566-B7961442-09C6-45C7-8564-6B5FAA673532Q33602336-71ECBE8E-4679-43AB-A391-E405844A5C72Q33752736-B1737048-A76D-4608-A1C7-8EA58652B4EAQ33760366-0FE018F1-C6A3-42A9-B369-89BB1379E1DBQ33954859-041206FD-B7F4-4361-90F0-E4048861E8D7Q33986159-22358831-6A27-4151-9EA4-C2FFCA01FA64Q34253039-AABE5FA2-F2D6-4698-934F-5AC6757EA64EQ34376622-62046A48-54FC-41AA-9CF6-6E07AEAAF7F4Q34602036-4AD8F632-D939-4E5C-AAC5-0B9BBF8C2D41Q35519250-BDD8B997-57B5-4C60-BC53-6EBF2C042DCAQ35681183-6D2C80A6-53BD-427C-BF0E-1065985571B9Q35888039-F7F0FD76-A454-4DCC-B56A-78B125BF4290Q36214917-6DB2A382-BE2F-43C7-8E6C-CCA74C2CBCD4Q36253134-A193FC02-1576-4DC8-A402-26843D0D8B26Q36307156-4DAA8913-4888-447A-B5E4-8D8EADC4D504Q36555415-81BFCDC1-81D7-42BE-9462-98A543400508Q36564390-F7552EDB-4FF8-40A9-8845-10DC5EBEF0AAQ36664896-F3ABAF8F-C570-4DF6-ABB7-BA89D8588A4DQ36949372-A268C216-E059-4669-B378-EB6AFDF1A7EBQ37055649-EC095EB6-FE1E-4422-A672-D499BE8AE90CQ37069946-0AD42163-1EB7-4EB8-A529-9FEA32F5145CQ37313106-554B5E9D-7638-42A5-8DAE-D372EF255B9BQ37883007-859B8485-2BFE-4189-83D9-E0FFFEA0B517Q38091540-D3910B3C-035F-400F-957F-13A41C5C29B7Q38177858-F72F79D5-1D37-47F9-B164-36B5E8977E56Q38245148-CB58BDA2-F076-4664-A4AF-9E0A9B4F573CQ38246679-3CED576D-0C59-47C9-A8CE-EDEFD2E1C894Q38270095-7021E032-9BDE-4E36-9183-04788E2542DBQ38615224-2EAAD5C0-113D-44DF-A4EA-68063F34ADF9Q38661142-FBC0E6D9-5283-419D-858A-F054D5CC3CB4Q38672888-6A0963F5-B69E-47D5-BC84-0AA7A04B8D47
P2860
Current status of gadolinium toxicity in patients with kidney disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Current status of gadolinium toxicity in patients with kidney disease.
@en
Current status of gadolinium toxicity in patients with kidney disease.
@nl
type
label
Current status of gadolinium toxicity in patients with kidney disease.
@en
Current status of gadolinium toxicity in patients with kidney disease.
@nl
prefLabel
Current status of gadolinium toxicity in patients with kidney disease.
@en
Current status of gadolinium toxicity in patients with kidney disease.
@nl
P356
P1476
Current status of gadolinium toxicity in patients with kidney disease.
@en
P2093
Mark A Perazella
P304
P356
10.2215/CJN.06011108
P577
2009-02-01T00:00:00Z